Wael Traboulsi

Wael Traboulsi

Auto-generated profile, based on publicly available information

Wael Traboulsi

Aix-Marseille Univ, INSERM1263, INRAE1260, C2VN, Marseille, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2015 in Hormone Molecular Biology and Clinical Investigation
Verified
Journal Article
Closed access
WTWael Traboulsi
Wael Traboulsi
SBSophie Brouillet
Sophie Brouillet
FSFrederic Sergent
Frederic Sergent
HBHoussine Boufettal
Houssine Boufettal
NSNaima Samouh
Naima Samouh
Nadia AlfaidyNadia Alfaidy
Nadia Alfaidy
Prokineticin 1 (PROK1) and (PROK2), are two closely related proteins that were identified as the mammalian homologs of their two amphibian homologs, mamba intestinal toxin (MIT-1) and Bv8. PROKs activate two G-protein linked receptors (prokineticin receptor 1 and 2, PROKR1 and PROKR2). Both PROK1 and PROK2 have been found to regulate a stunning array of biological functions. In particular, PROKs stimulate gastrointestinal motility, thus accounting for their family name “prokineticins”. PROK1 acts as a potent angiogenic mitogen, thus earning its other name, endocrine gland-derived vascular endothelial factor. In contrast, PROK2 signaling pathway has been shown to be a critical regulator of olfactory bulb morphogenesis and sexual maturation. During the last decade, strong evidences established the key roles of prokineticins in the control of human central and peripheral reproductive processes. PROKs act as main regulators of the physiological functions of the ovary, uterus, placenta, and testis, with marked dysfunctions in various pathological conditions such as recurrent pregnancy loss, and preeclampsia. PROKs have also been associated to the tumor development of some of these organs. In the central system, prokineticins control the migration of GnRH neurons, a key process that controls reproductive functions. Importantly, mutations in PROK2 and PROKR2 are associated to the development of Kallmann syndrome, with direct consequences on the reproductive system. This review describes the finely tuned actions of prokineticins in the control of the central and peripheral reproductive processes. Also, it discusses future research directions for the use of these cytokines as diagnostic markers for several reproductive diseases.

19 October 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
AJAhmad Joshkon
Ahmad Joshkon
WTWael Traboulsi
Wael Traboulsi
MTMagali Terme
Magali Terme
RBRichard Bachelier
Richard Bachelier
HFHUSSEIN FAYYAD-KAZAN
HUSSEIN FAYYAD-KAZAN
MBMarcel Blot-Chabaud
Marcel Blot-Chabaud
Tumor development necessitates immune escape through different mechanisms. To counteract these effects, the development of therapies targeting immune checkpoints (ICP) has generated interest as they have produced lasting objective responses in patients with advanced metastatic tumors. However, many tumors do not respond to inhibitors of ICPs, necessitating to further study the underlying mechanisms of exhaustion. VEGFa, a proangiogenic molecule secreted by tumors, was described to participate to tumor immune exhaustion by increasing ICPs, justifying in part the use of an anti-VEGFa mAb, bevacizumab, in patients. However, recent studies from our group have demonstrated that tumors can escape anti-VEGFa therapy through the secretion of soluble CD146 (sCD146). In this study, we show that both VEGFa and sCD146 cooperate to create an immunosuppressive microenvironment by increasing the expression of ICPs. In addition, sCD146 favors protumoral M2-type macrophages and induces the secretion of proinflammatory cytokines. An anti-sCD146 mAb reverses these effects and displays additive effects with the anti-VEGFa antibody to eliminate tumors in a syngeneic murine model grafted with melanoma cells. Combining bevacizumab with mucizumab could thus be of major therapeutic interest to prevent immune escape in malignant melanoma and other CD146-positive tumors.

4 February 2025
Verified
Other
Open access
AJAhmad Joshkon
Ahmad Joshkon
WTWael Traboulsi
Wael Traboulsi
MTMagali Terme
Magali Terme
RBRichard Bachelier
Richard Bachelier
HFHUSSEIN FAYYAD-KAZAN
HUSSEIN FAYYAD-KAZAN
MBMarcel Blot-Chabaud
Marcel Blot-Chabaud
Suppl Figure 8 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy

4 February 2025
Verified
Other
Open access
AJAhmad Joshkon
Ahmad Joshkon
WTWael Traboulsi
Wael Traboulsi
MTMagali Terme
Magali Terme
RBRichard Bachelier
Richard Bachelier
HFHUSSEIN FAYYAD-KAZAN
HUSSEIN FAYYAD-KAZAN
MBMarcel Blot-Chabaud
Marcel Blot-Chabaud
Suppl Figure 11 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy

4 February 2025
Verified
Other
Open access
AJAhmad Joshkon
Ahmad Joshkon
WTWael Traboulsi
Wael Traboulsi
MTMagali Terme
Magali Terme
RBRichard Bachelier
Richard Bachelier
HFHUSSEIN FAYYAD-KAZAN
HUSSEIN FAYYAD-KAZAN
MBMarcel Blot-Chabaud
Marcel Blot-Chabaud
Suppl Figure 5 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy

4 February 2025
Verified
Other
Open access
AJAhmad Joshkon
Ahmad Joshkon
WTWael Traboulsi
Wael Traboulsi
MTMagali Terme
Magali Terme
RBRichard Bachelier
Richard Bachelier
HFHUSSEIN FAYYAD-KAZAN
HUSSEIN FAYYAD-KAZAN
MBMarcel Blot-Chabaud
Marcel Blot-Chabaud
Suppl Figure 2 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy